RE:RE:RE:RE:Madrigal picked by Goldman for MA we all thought Nash protocols and fda approval for phase 3 would bust the lack of valuation wide open and yet here we are months later with a lower sp and on the heels of another offering where we all get diluted once again. I'm keeping my fingers crossed for cancer but if pats is any indication of the future they still will get a muted reaction unless cancer shows efficacy, then we will be trying to start p2 b in the middle of another public freak out of the pandemic.
Bucknelly21 wrote:
I know I'm just exhausted waiting for them to get it. It's costs all of us. Now it feels like we will be getting results right in the middle of omicron. Just hard to watch so many others get it right in dealing with capital markets and Thtx fail after fail. You have a group of people with various backgrounds that provide a lot of valuable insight yet you can't seem to accomplish the most basic part of being a company with promising prospects. It shouldn't be this hard. I get bio tech is crazy but the things they are struggling with is not that crazy. Honestly, transparency and a little promotion. You have a bloated payroll with a massive valuation gap to comparable companies. So yeah I'm in a mood and just feel beat down by the fact the writing is on the wall for these guys yet they march to the same old beat and expect things to change
CreatingApe wrote:
ahh good ol buck... always so positive with helpful insights :)